ClinicalTrials.gg
Not yet recruitingNCT06722690Updated Nov 4, 2026

eTSF for Latinx Young Adults With Alcohol Use Disorder

An interventional study of eTSF and Educational materials in Alcohol Use Disorder (AUD), sponsored by University of Texas at Austin. Not yet recruiting. Open to participants aged 18 Years to 29 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Texas at Austin · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedSponsor changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 29 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the eTSF intervention is feasible among Latinx young adults with alcohol use disorder. The main questions it aims to answer are:

  • Is eTSF feasible?
  • Is eTSF effective in reducing alcohol use and increasing 12-step engagement compared to the control condition? The control condition will receive educational materials on drinking problems and a list of local/online AA meetings Participants will
  • Be randomly assigned to either the eTSF condition or the control condition.
  • Fill out the baseline online survey.
  • Go through the eTSF app/control materials.
  • And at 3 months post-baseline, fill out the follow-up online survey.
02

Conditions studied

  • Alcohol Use Disorder (AUD)

Browse trials for

03

In context

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

This study's planned enrollment of 40 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

University of Texas at Austin is the lead sponsor of 328 studies on the registry; 79 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • YAs age 18-29
  • Identify as Latinx
  • Meet the Diagnostic \& Statistical Manual of Mental Disorders 5th edition () diagnostic criteria for alcohol use disorder
  • Are at least minimally motivated to change their drinking (i.e., scoring ≥3 on the University of Rhode Island Change Assessment Scale's contemplation, action, or maintenance subscales and ≤3 on the precontemplation subscale)
  • Be able to provide at least one contact person to assist in tracking them for follow-up assessment

Exclusion criteria

Exclusion Criteria:

  • Attending any 12-step program (≥2 meetings in the past month)
  • Experiencing psychotic symptoms or cognitive impairment
  • In alcohol or drug treatment programs
  • Taking addiction treatment medications
  • Experiencing, expecting to experience, or had a history of severe/complicated withdrawal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    eTSF

    This arm will receive the eTSF intervention. eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.

    Behavioral: eTSF

  • Active comparator
    Educational control

    This arm will receive educational materials on drinking problems and a list of local/online AA meetings

    Behavioral: Educational materials

Interventions

  • BehavioraleTSF

    eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.

  • BehavioralEducational materials

    Educational materials on drinking problems and a list of local/online AA meetings.

06

What researchers measure

Primary outcomes

  1. Recruitment feasibility

    Recruitment feasibility will be measured by the number of participants screened and enrolled each month.

    Time frame: Every 4 weeks up to 2 years

  2. Randomization feasibility

    Randomization feasibility will be measured by the number of baseline demographic variables with statistically significant group differences.

    Time frame: From recruitment to baseline assessment up to two years

  3. Retention/attrition feasibility

    Retention/attrition feasibility will be measured by retention rates in each condition.

    Time frame: From recruitment to the end of the trial at three months.

  4. Adherence feasibility

    Adherence feasibility will be measured by the percentage of eTSF app components used by the eTSF condition participants.

    Time frame: From recruitment to the end of the trial at three months.

  5. Assessment feasibility

    Assessment feasibility will be measured by the proportion of missing data in each assessment.

    Time frame: From recruitment to the end of the trial at three months.

  6. Intervention credibility

    Intervention credibility will be measured using a single-item question: "On a scale from 1 to 5, where 1 indicates 'not at all' and 5 indicates 'very much,' to what extent do you believe this treatment will be beneficial for you?" Only eTSF condition participants will receive this measure.

    Time frame: From baseline to the end of treatment at three months.

  7. Intervention satisfaction

    Intervention satisfaction will be measured using the mHealth Satisfaction Questionnaire, which has a total score range from 14 to 42. Higher total scores indicate greater user satisfaction with the mHealth app.

    Time frame: From baseline to the end of treatment at three months.

  8. Intervention acceptability

    Acceptability will be measured using the Abbreviated Acceptability Rating Profile, which scores range from 8 to 48. Higher scores indicate greater acceptability of the intervention.

    Time frame: From baseline to the end of treatment at three months.

  9. Intervention engagement

    Intervention engagement will be automatically recorded by the app during the study period and be measured in terms of app opening frequency, time spent on the app per use session (i.e., the time between opening and closing the app), most frequently used intervention component, time spent per intervention component, the completion rate of each selected component, reports of technical problems.

    Time frame: From baseline to the end of treatment at three months.

Secondary outcomes

  1. Alcohol use

    Alcohol use will be measured using the Time-Line Follow-Back (TLFB) method-Form 90, which helps participants recall and mark days on which they used alcohol during the past 90 days.

    Time frame: From baseline to the end of treatment at three months.

  2. 12-Step fellowship engagement

    12-Step fellowship engagement will be measured with the Multi-Dimensional Mutual-help Activity Scale (MDMAS), which measures seven dimensions of experience (meeting attendance, meeting participation, fellowship involvement, step work, mandated attendance, affiliation, and safety). Total score ranges from 32-160 with higher scores within indicating greater engagement.

    Time frame: From baseline to the end of treatment at three months.

Other outcomes

  1. Drinking consequences

    Drinking consequences will be measured with the Short Inventory of Problems (SIP-2R). Score ranges from 0-45 with higher scores indicating a greater frequency of experiencing problems related to substance use.

    Time frame: From baseline to the end of treatment at three months.

  2. Drug use

    Drug use will be measured with the aforementioned TLFB-Form 90

    Time frame: From baseline to the end of treatment at three months.

  3. Psychological distress

    Psychological distress will be assessed with the 18-item Brief Symptom Inventory. Score ranges 0-72 and higher scores indicate greater levels of psychological distress.

    Time frame: From baseline to the end of treatment at three months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The IPD will be shared on the NIAAA Data Archive.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Aug 2028, 15 months later.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 15 months is below that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

Start moved twice since we started tracking on Sep 25, 2026: Jan 2027 → May 2027, last on Nov 4, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2028 → Aug 2028, on Oct 13, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2029 → Aug 2029, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 9, 2024
StartEst.
May 2027was Jan 2027
Primary completionEst.
Aug 2028was Dec 2028
CompletionEst.
Aug 2029was Feb 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 2027→May 2027
moved 2 times, Oct 13, 2026 – Nov 4, 2026
Primary completion
Dec 2028→Aug 2028
Oct 13, 2026
Study completion
Feb 2029→Aug 2029
Oct 13, 2026
Sponsor
Tulane University→University of Texas at Austin
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    Start date Aug 2027→May 2027
    Sponsor Tulane University→University of Texas at Austin
    + 1 other change: identifiers
  2. Oct 13, 2026
    Start date Jan 2027→Aug 2027
    Primary completion Dec 2028→Aug 2028
    Study completion Feb 2029→Aug 2029
    + 5 other changes: identifiers, verification date, responsible party, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06722690
Responsible party
Hang Hai (Associate Professor, University of Texas at Austin) — Principal investigator
First posted
Dec 9, 2024
Start date
May 2027 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Hang Hai
Contact
ahai@tulane.edu
504-247-1457

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion